Remission in children and adolescents diagnosed with attention-deficit/ hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate

Journal of Child and Adolescent Psychopharmacology

Volumn 22, Issue 3, 2012, Pages 215-225

  Chou, Wen Jiun ^a   Chen, Shin Jaw ^b   Chen, Ying Sheue ^c   Liang, Hsin Yi ^a   Lin, Chih Chien ^d   Tang, Ching Shu ^a   Huang, Yu Shu ^a   Yeh, Chin Bin ^e   Chou, Miao Chun ^a   Lin, Dai Yueh ^c   Hou, Po Hsun ^d   Wu, Yu Yu ^a   Liu, Hung Jen ^c   Huang, Ya Fen ^a   Hwang, Kai Ling ^c   Chan, Chin Hong ^d   Pan, Chia Ho ^c   Chang, Hsueh Ling ^a   Huang, Chi Fen ^a   Hsu, Ju Wei ^c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b Dr Yin's Clinic   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DAY DREAMING; DECREASED APPETITE; DISEASE SEVERITY; DROWSINESS; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DSM-IV; EMOTION; FEMALE; HABIT; HEADACHE; HUMAN; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; NIGHTMARE; OPTIMAL DRUG DOSE; OSMOTIC RELEASE ORAL SYSTEM; PATIENT SATISFACTION; PNEUMONIA; PRESCHOOL CHILD; RATING SCALE; REMISSION; SCHOOL CHILD; SCORING SYSTEM; SENTIMENTAL; SHOCK; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; SWANSON, NOLAN, AND PELHAM, VERSION IV; TAIWAN; TIC; TREATMENT RESPONSE; TROUBLE SLEEPING; UNUSUALLY HAPPY; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHYLPHENIDATE; OSMOTIC PRESSURE; PARENTS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84862493364     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0006     Document Type: Article

References (52)

1. American Academy of Pediatrics. Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105:1158-1170, 2000.
2. American Academy of Pediatrics. Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108:1033-1044, 2001.
3. Anderson IM, Nutt DJ, Deakin JF: Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 14:3-20, 2000. (Pubitemid 30156533)
4. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR: Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry 162:441-449, 2005. (Pubitemid 40343909)
5. Barkley RA, Fischer M, Edelbrock C, Smallish L: The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 29:546-557, 1990. (Pubitemid 20235340)
6. Barkley RA, Fischer M, Smallish L, Fletcher K: Young adult outcome of hyperactive children: Adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 45:192-202, 2006. (Pubitemid 43151524)
7. Biederman J, Faraone S, Milberger S, Curtis S, Chen L, Marrs A, Ouellette C, Moore P, Spencer T: Predictors of persistence and remission of ADHD into adolescence: Results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 35:343-351, 1996. (Pubitemid 26072292)
8. Biederman J, Mick E, Faraone SV: Normalized functioning in youths with persistent attention-deficit/hyperactivity disorder. J Pediatr 133:544-551, 1998. (Pubitemid 28465383)
9. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV: Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): Effects of ADHD and psychiatric comorbidity. Am J Psychiatry 152:1652-1658, 1995.
10. Canadian Psychiatric Association Network for Mood and Anxiety Treatments: Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 46:5S-90S, 2001.
11. Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H: Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosci 63:167-175, 2009.
12. Conners C: Connners' Rating Scale-Revised. North Tonawanda, NY: Multi-Health Systems; 1997.
13. Dickson RA, Maki E, Gibbins C, Gutkin SW, Turgay A, Weiss MD: Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: Analysis of Canadian open-label studies. Child Adolesc Psychiatry Ment Health 5:14, 2011.
14. Findling RL, Kauffman RE, Sallee FR, Carson WH, Nyilas M, Mallikaarjun S, Shoaf SE, Forbes RA, Boulton DW, Pikalov A: Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: An open-label, dose-escalation study. J Clin Psychopharmacol 28:441-446, 2008.
15. Fischer M, Barkley RA, Smallish L, Fletcher K: Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 30:463-475, 2002. (Pubitemid 38471276)
16. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851-855, 1991.
17. Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tzang RF, Wu YY, Huang YF, Chou MC, Liang HY, Hsu YC, Lu HH, Huang YS: National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry 69:131-140, 2008a. (Pubitemid 351282007)
18. Gau SS, Huang YS, Soong WT, Chou MC, Chou WJ, Shang CY, Tseng WL, Allen AJ, Lee P: A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17:447-460, 2007. (Pubitemid 47417773)
19. Gau SS, Shang CY, Liu SK, Lin CH, Swanson JM, Liu YC, Tu CL: Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, version IV scale - parent form. Int J Methods Psychiatr Res 17:35-44, 2008b.
20. Gau SS, Shen HY, Soong WT, Gau CS: An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol 16:441-455, 2006. (Pubitemid 44681464)
21. Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, McGough J, Wigal S, Wigal T, Vitiello B, Skrobata A, Posner K, Ghuman J, Cunningham C, Davies M, Chuang S, Cooper T: Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45:1284-1293, 2006. (Pubitemid 44665445)
22. Hechtman L, Abikoff H, Klein RG, Weiss G, Respitz C, Kouri J, Blum C, Greenfield B, Etcovitch J, Fleiss K, Pollack S: Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 43:812-819, 2004. (Pubitemid 38808486)
23. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ: Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 114:e1-8, 2004.
24. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS: Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: A multicenter, randomized prospective study. Adv Ther 22:498-512, 2005. (Pubitemid 43130867)
25. Kupfer DJ: Long-term treatment of depression. J Clin Psychiatry. 52(Suppl): 28-34, 1991.
26. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S: International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11-28, 2004. (Pubitemid 37495027)
27. Lam RW, Kennedy SH: Evidence-based strategies for achieving and sustaining full remission in depression: Focus on meta-analyses. Can J Psychiatry 49:17S-26S, 2004. (Pubitemid 38506488)
28. Mannuzza S, Klein RG, Bessler A, Malloy P, Hynes ME: Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 36:1222-1227, 1997. (Pubitemid 27381278)
29. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901, 2002. (Pubitemid 35283256)
30. Mohammadi MR, Akhondzadeh S: Pharmacotherapy of attentiondeficit/ hyperactivity disorder: Nonstimulant medication approaches. Expert Rev Neurother 7:195-201, 2007. (Pubitemid 46434167)
31. MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086, 1999.
32. MTA Cooperative Group: National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 113:754-761, 2004.
33. Newcorn JH, Stein MA, Cooper KM: Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylpheniate in a 4-week, open-label, dose-titration study. J Child Adolesc Psychopharmacol 20:187-196, 2010.
34. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD: Once-aday Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105, 2001.
35. Ramos-Quiroga JA, Casas M: Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder. CNS Drugs 25:17-36, 2011.
36. Remschmidt H: Global consensus on ADHD/HKD. Eur Child Adolesc Psychiatry 14:127-137, 2005.
37. Satterfield JH, Schell A: A prospective study of hyperactive boys with conduct problems and normal boys: Adolescent and adult criminality. J Am Acad Child Adolesc Psychiatry 36:1726-1735, 1997. (Pubitemid 27512327)
38. Schimmelmann BG, Mehler-Wex C, Lambert M, Schulze-zur-Wiesch C, Koch E, Flechtner HH, Gierow B, Maier J, Meyer E, Schulte-Markwort M: A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol 17:768-778, 2007. (Pubitemid 351158602)
39. Spencer T, Biederman J, Wilens T, Faraone S, Prince J, Gerard K, Doyle R, Parekh A, Kagan J, Bearman SK. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 58:775-782, 2001. (Pubitemid 32717803)
40. Steele M, Jensen PS, Quinn DM: Remission versus response as the goal of therapy in ADHD: A new standard for the field? Clin Ther 28:1892-1908, 2006a. (Pubitemid 46038524)
41. Steele M, Prinzo R, Binder C: Long-term effectiveness and safety of Concerta in children with ADHD: a six-month study. American Psychiatric Association. Annual Meeting, 2005a (Abstract NR 436).
42. Steele M, Prinzo R Binder C: The maintenance of effectiveness of Concerta in children with ADHD: An eight-month analysis. Washington (DC), American Psychiatric Association. Annual Meeting, 2005b (Abstract NR 434).
43. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE: A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 13:e50-62, 2006b. (Pubitemid 46165597)
44. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH: A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112:e404, 2003.
45. Swan J: SNAP-IV Scale. Irvine, CA: University of California, Irvine Child Development Center; 1995.
46. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M: Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40:168-179, 2001. (Pubitemid 32111020)
47. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ: A comparison of once-daily extended-release methylphenidate formulations in children with attention deficit/hyperactivity disorder in the laboratory school (the COMACS Study). Pediatrics 113:e206-216, 2004.
48. Wang YC, Chong MY, Chou WJ, Yang JL: Prevalence of attention deficit hyperactivity disorder in primary school children in Taiwan. J Formos Med Assoc 92:133-138, 1993.
49. Weiss G, Hechtman L, Milroy T, Perlman T: Psychiatric status of hyperactive as adults: A controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 24:211-220, 1985. (Pubitemid 15100202)
50. Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL, Wigal TL, Kollins SH, Clark TM, Mays DA, Zhang Y, Tulloch SJ: A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 9:275-289, 2005. (Pubitemid 41551759)
51. Wilens TE, Spencer TJ: The stimulants revisited. Child Adolesc Psychiat Clin N Am 9:573-603, 2000. (Pubitemid 30620545)
52. Yang P, Chung LC, Chen CS, Chen CC: Rapid improvement in academic grades following methylphenidate treatment in attention-deficit hyperactivity disorder. Psychiatry Clin Neurosci 58:37-41, 2004. (Pubitemid 38200369)